Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Genzyme Bid For Impath Unit Reflects Efforts To Raise Oncology Profile

This article was originally published in The Gray Sheet

  • News

Executive Summary

Genzyme will gain access to an expanded menu of cancer diagnostic tests and physician services if a pending $215 mil. cash bid for Impath's cancer testing unit proves successful

You may also be interested in...



Genzyme Licenses Biomarker To Develop Lung Cancer Companion Diagnostic

Genzyme's development of a lung cancer drug companion diagnostic would represent the firm's first in-house oncological test offering

Genzyme Licenses Biomarker To Develop Lung Cancer Companion Diagnostic

Genzyme's development of a lung cancer drug companion diagnostic would represent the firm's first in-house oncological test offering

Synvisc OA Therapy Boosts Margins, Holds Promise For New Indications

Genzyme's recent reacquisition of marketing rights to the Synvisc knee osteoarthritis treatment will help the firm realize a hefty gross margins increase in 2005

Table

View full table

Tags:
Latest Headlines

Second EU MDR Notified Body Designated In France

Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217

CDS Final Guidance Draws More Criticism, This Time From Congress

Alarming Rise Of Diabetes in Several US States, Study Shows

See All
UsernamePublicRestriction

Register

MT019871

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By